08. October 2019

Zedira ISO9001:2015 certification

Zedira kits

Zedira Logo                                                                                                                                                                     Transglutaminase-Newsletter | October 2019

Dear valued customer,

Diagnostic and pharmaceutical industries are subject to increasing regulatory demands.

It is our pleasure to inform you that Zedira, provider of raw materials and services, complies with said requirements by the implementation of the management system as per

DIN EN ISO 9001:2015

Evidence of conformity with the above standards was verified and is certified in accordance with "TÜV PROFiCERT" procedures.

Certificate valid from 2019-09-13
Certificate registration No. 73 100 6469

Scope: Research, development, production, and distribution in the area of biotechnology.

Download Certificate
Z190913-english.pdf (English Version)
Z190913-deutsch.pdf (German Version)

Zedira offers raw materials for diagnostics and API production:

Microbial Transglutaminase –
Zedira’s tool for site specific conjugation in Antibody Drug Conjugate production

Art. No. Name Unit Price


Microbial (bacterial) transglutaminase
(MTG, recombinantly produced in E. coli, gene derived from Streptomyces mobaraensis)
25 U
10x 25 U
20x 25 U

270 €
2140 €
3750 €

Microbial (bacterial) transglutaminase
Characterized for content of host cell protein (HCP), host cell DNA , endotoxin, and microbial burden
25 U
10x 25 U
20x 25 U

370 €
2950 €
5150 €
T178 Microbial transglutaminase with C-terminal His6-Tag 25 U
10x 25 U
20x 25 U

370 €
2950 €
5150 €
Z009 ZediXclusive Microbial Transglutaminase Assay Kit 1 Kit

310 €

Zedira’s Diagnostic Antigens

Art. No. Name Unit Price


Recombinant TG2 (insect cells)
Tissue transglutaminase
Autoantigen in celiac disease

250 µg

370 €


Human neuronal transglutaminase
(TG6, recombinantly produced in insect cells)
Autoantigen in gluten ataxia

250 µg 475 €

Recombinant TG3 (insect cells)
Epidermal transglutaminase
Autoantigen in dermatitis herpetiformis

200 µg

370 €


DGPx1 (deamidated gliadin peptide)
Antigen in celiac disease

500 µg 735 €

DGPx2 (Fusion protein of 2 deamidated gliadin peptides)
Antigen in celiac disease

500 µg 735 €

Assay substances and assays

Art. No. Name Unit Price


FXIII-Assay Substance, Abz-NE(CAD-DNP)EQVSPLTLLK-OH 10 mg 520 €

FXIII-Assay Kit 1 Kit 575 €

Zedira’s Enzymes for diagnostics

Art. No. Name Unit Price


Human Plasmin, recombinant
Blood coagulation, plasmin inhibitor assay

100 µg 415 €

Human Factor XIIIa, activated
Blood coagulation, TEM/TEG

 200 µg 520 €


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA